FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 359:1836-1838 October 23, 2008 Number 17 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Bochud, P.-Y. PubMed Citation

Allogeneic hematopoietic stem-cell transplantation is a potentially lifesaving cancer therapy that, at least temporarily, renders patients highly immunocompromised and vulnerable to infection. Aspergillus fumigatus, a common environmental fungus that causes invasive infections in immunocompromised persons, is particularly problematic in patients who have undergone this treatment.¹ Although the risk of the development of aspergillosis correlates with the degree of immunosuppression and the intensity of exposure to fungal spores, these factors alone do not explain why this infection develops in approximately 5 to 10% of patients who have received these transplants, whereas it does not develop in the remaining 90 to 95% . . . [Full Text of this Article]

Source Information

From Memorial Sloan-Kettering Cancer Center, New York.

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.